Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Most are asking is an investment in InflaRx worth it? Presumably, this question is in response to the FDA regulatory hurdle currently playing out with the NDA for avacopan by ChemoCentryx. On ChemoCentryx, you need to read my latest article. Regardless of what is happening at ...
Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021. Regulatory review is ongoing with the PDUFA extended to Oct. 6, 2021, in response to new filing by CCXI which the FDA designated as a major amendment to the NDA. ...
Image source: The Motley Fool. ChemoCentryx, inc (NASDAQ: CCXI) Q2 2021 Earnings Call Aug 9, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: ChemoCentryx, inc (CCXI) Q2 2021 Earnings Call Transcript
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: ChemoCentryx, Inc. 2021 Q2 - Results - Earnings Call Presentation
ChemoCentryx, Inc. (CCXI) Q2 2021 Earnings Conference Call August 9, 2021 17:00 ET Corporate Participants Lee Roth - Burns McClellan, IR Tom Schall - President and Chief Executive Officer Susan Kanaya - Executive Vice President, Chief Financial and Administrative Officer ConferenceCall Partic...
-- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021-- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis also under review by the European Medicines Agenc...
SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 a...
MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market close on Monday, August 9, 2021. ChemoCentryx executive management will host a conference call ...
ACHC, ADUS, ANET, AWK, BCC, BRKR, BRX, BWXT, CCXI, CLR, COLM, EMN, EVER, FANG, FRPT, HLIT, HMN, KMT, LEG, MOS, NSP, NXPI, O, OGS, OHI, OTTR, PXD, RARE, REYN, RIG, RMBS, SANM, SBAC, SEDG, SPG, SYKE, TREX, TTWO, UCTT, UIS, UNVR, VNO, VNOM, VRNS, WMB, WWD, ZI For Seeking Alpha's full earnings se...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...